AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 12.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,037,348 shares of the medical device company's stock after selling 149,584 shares during the period. Nuveen Asset Management LLC owned approximately 2.13% of AtriCure worth $31,701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hood River Capital Management LLC raised its stake in shares of AtriCure by 3.3% during the 4th quarter. Hood River Capital Management LLC now owns 2,923,731 shares of the medical device company's stock valued at $89,349,000 after buying an additional 93,131 shares during the last quarter. First Light Asset Management LLC raised its stake in shares of AtriCure by 5.6% during the 4th quarter. First Light Asset Management LLC now owns 1,969,221 shares of the medical device company's stock valued at $60,179,000 after buying an additional 103,685 shares during the last quarter. Kennedy Capital Management LLC raised its stake in shares of AtriCure by 29.8% during the 4th quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock valued at $22,999,000 after buying an additional 172,648 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of AtriCure by 24.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock valued at $21,398,000 after buying an additional 136,015 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of AtriCure by 37.1% during the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock valued at $18,922,000 after buying an additional 167,476 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ATRC shares. UBS Group reduced their price objective on AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a research note on Thursday, March 27th. Needham & Company LLC reduced their price objective on AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Piper Sandler raised their target price on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, Canaccord Genuity Group dropped their target price on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research report on Friday, March 28th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $50.67.

Insider Buying and Selling

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. The trade was a 25.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 3.50% of the stock is currently owned by insiders.

AtriCure Price Performance

ATRC stock traded up $1.28 during trading on Tuesday, hitting $33.99. The stock had a trading volume of 412,582 shares, compared to its average volume of 650,035. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The stock has a market capitalization of $1.68 billion, a P/E ratio of -35.78 and a beta of 1.57. The company's 50-day moving average price is $32.32 and its two-hundred day moving average price is $34.74.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The company had revenue of $123.62 million for the quarter, compared to analysts' expectations of $122.92 million. During the same period in the previous year, the firm posted ($0.28) EPS. AtriCure's revenue was up 13.5% compared to the same quarter last year. As a group, research analysts predict that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.